Cardiff Oncology Stock Forecast

CRDF's stock price has decreased by -56.68% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 7 analysts polled by S&P Global, Cardiff Oncology stock has a consensus rating of "Buy" and an average price target of $5.10. The average 1-year stock price forecast is 442.55% higher than the current stock price, while the lowest is $1.20 (+27.66%) and the highest is $12 (+1,176.60%).

Price Target: $5.10 (+442.55%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$1.20	$5.10	$4.00	$12
Change	+27.66%	+442.55%	+325.53%	+1176.6%

Analyst Ratings

The average analyst rating for Cardiff Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Aug '26
Strong Buy	6	6	6	6	3	2
Buy	1	1	1	1	1	1
Hold	1	1	1	1	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $6	Buy	Reiterates	$6	+538.30%	Aug 12, 2026
Marc Frahm TD Cowen	TD Cowen	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Aug 11, 2026
Andy Hsieh William Blair	William Blair	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Aug 11, 2026
Christopher Liu Lucid Capital	Lucid Capital	Buy Maintains $10 → $4	Buy	Maintains	$10 → $4	+325.53%	Jun 5, 2026
Albert Lowe Craig-Hallum	Craig-Hallum	Hold Downgrades $2	Hold	Downgrades	$2	+112.77%	Jun 3, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

260.14K

from 593.00K

-56.13%

from 593.00K

Revenue Next Year

220.83K

from 260.14K

-15.11%

from 260.14K

EPS This Year

-0.55

from -0.69

EPS Next Year

-0.59

from -0.55

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	359.00K	386.00K	488.00K	683.00K	593.00K	260.14K
Revenue Growth	-1.91%	7.52%	26.42%	39.96%	-13.18%	-56.13%
Operating Income	-28.86M	-39.90M	-45.41M	-48.65M	-48.96M	-45.65M
Net Income	-28.29M	-38.70M	-41.44M	-45.43M	-45.85M	-44.32M
EPS	-	-	-	-	-0.69	-0.55
Free Cash Flow	-16.74M	-21.04M	-18.01M	-22.53M	-19.62M	-48.00M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	440,000
Avg	260,140
Low	100,000

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-25.8%
Avg	-56.1%
Low	-83.1%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.50
Avg	-0.55
Low	-0.60

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-